Abstract:Cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), result from an impairment of bile flow that leads to the hepatic retention of bile acids, causing liver injury. Until recently, the only approved treatments for PBC were ursodeoxycholic acid (UDCA) and obeticholic acid (OCA). While these therapies slow the progression of PBC in the early stage of the disease, approximately 40% of patients respond incompletely to UDCA, and advanced cases do not respond. UDCA does not improve survival in patients with PSC, and patients often have dose-limiting pruritus reactions to OCA. Left untreated, these diseases can progress to fibrosis and cirrhosis, resulting in liver failure and the need for transplantation. These shortcomings emphasize the urgent need for alternative treatment strategies. Recently, nuclear hormone receptors have been explored as pharmacological targets for adjunct therapy because they regulate enzymes involved in bile acid metabolism and detoxification. In particular, the peroxisome proliferator-activated receptor (PPAR) has emerged as a therapeutic target for patients with PBC or PSC who experience an incomplete response to UDCA. PPARα is predominantly expressed in the liver, and it plays an essential role in the regulation of cytochrome P450 (CYP) and uridine 5'-diphospho-glucuronosyltransferase (UGT) enzymes, both of which are critical enzyme families involved in the regulation of bile acid metabolism and glucuronidation, respectively. Importantly, PPARα agonists, e.g., fenofibrate, have shown therapeutic benefits in reducing elevated markers of cholestasis in patients with PBC and PSC, and elafibranor, the first PPAR (dual α, β/δ) agonist, has been FDA-approved for the second-line treatment of PBC. Additionally, newer PPAR agonists that target various PPAR isoforms (β/δ, γ) are under development as an adjunct therapy for PBC or PSC, although their impact on glucuronidation pathways are less characterized. This review will focus on PPAR-mediated bile acid glucuronidation as a therapeutic pathway to improve outcomes for patients with PBC and PSC.

Nuclear receptors as drug targets in cholestasis

Farnesoid X receptor modulators 2014-present: a patent review

Mechanism of Hydrophobic Bile Acid-Induced Hepatocyte Injury and Drug Discovery

Novel and emerging therapies for cholestatic liver diseases

Drug targets regulate systemic metabolism and provide new horizons to treat nonalcoholic steatohepatitis

Nuclear receptors as targets for drug development: regulation of cholesterol and bile acid metabolism by nuclear receptors

Therapeutic Role of Bile Acids and Nuclear Receptor Agonists in Fibrosing Cholangiopathies

Current Status of Cholestasis: Pathogenesis, Diagnosis and Treatment

Advance in the research on several nuclear receptors related to bile acid metabolism

FXR: structures, biology, and drug development for NASH and fibrosis diseases

Primary biliary cholangitis: pathogenesis and therapeutic opportunities

Primary biliary cholangitis: molecular pathogenesis perspectives and therapeutic potential of natural products

Natural products for the prevention and treatment of cholestasis: A review

Novel therapeutic targets in primary biliary cirrhosis

PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases

Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics

Drug disposition in cholestasis: An important concern

Therapeutic targets for cholestatic liver injury

Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH

Metabolomic Analysis Reveals the Therapeutic Effects of MBT1805, a Novel Pan-Peroxisome Proliferator-Activated Receptor Agonist, on Α-Naphthylisothiocyanate-induced Cholestasis in Mice

Nuclear receptors: pathophysiological mechanisms and drug targets in liver disease